Collaboration will investigate non-controversial source of potential stem cell therapies for premature babies
This collaboration will study and promote the discovery of methods for optimizing collection of umbilical cord blood and cord tissue stem cells following premature births, providing a valuable resource for potential therapeutic use. Participating families will benefit from complimentary collection of their baby's umbilical cord blood, which has been shown to treat nearly 80 life-threatening diseases, and cord tissue, a rich source of mesenchymal stem cells expected to play an important role in regenerative medicine.
The study will focus on infants born prior to the 34th week
of pregnancy and findings will provide insight into the unique
characteristics of umbilical cord blood and tissue stem cells of babies
born prematurely. Throughout the study, researchers will obtain data
surrounding cord blood and cord tissue stem cell collection in premature
infants, including volume, tissue mass, cellular composition and other
variables. Collections for the study will be taken at
"The therapeutic benefits of umbilical cord blood and cord tissue stem
cells have the potential to address significant unmet need in the
treatment of severe illnesses in premature babies," said
"Our collaboration with ViaCord aligns with our goal of holistically
providing support for families with premature infants," said
Individuals born prematurely have shown to be more susceptible to a
range of health complications, including intellectual disability, lung
problems and vision and hearing loss. A recent study published in the
For more information about the study and collaboration between ViaCord and Miracle Babies, please visit www.miraclebabies.org.
ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood and cord tissue for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. Please visit www.viacord.com for more information.
About Miracle Babies
Our mission is to provide education, support, and financial assistance to families with newborns in the neonatal intensive care unit (NICU). Every year more than 500,000 babies are born prematurely. As overwhelmed families grapple with the terrifying uncertainties, they often find themselves faced with unexpected financial difficulties. With something so precious to lose, it is important that we give as much as we can. To learn more about how you can help Miracle Babies, please visit http://www.miraclebabies.org.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
Edelman (On behalf of PerkinElmer, Inc.)
Source: PerkinElmer, Inc.
News Provided by Acquire Media